Search research articles
Contact Us
Filters
Showing results (11-20 of 210) with videos related to
Page
of 21
Sort By:
Journal of the National Cancer Institute
|
November 25, 2010
Meta-analysis: should it be more than the sum of its parts?
Pia Herbolsheimer, Sandra M Swain
NPJ Breast Cancer
|
May 21, 2021
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Ilana Schlam, Sandra M Swain
Expert Opinion on Drug Safety
|
March 17, 2016
Pertuzumab for the treatment of breast cancer: a safety review
Jennifer Gao, Sandra M Swain
Clinical Breast Cancer
|
December 15, 2010
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer
José Baselga, Sandra M Swain
Cancer
|
May 27, 2010
Primary systemic chemotherapy for inflammatory breast cancer
Sarah Sinclair, Sandra M Swain
Nature Reviews. Cancer
|
June 19, 2009
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
José Baselga, Sandra M Swain
Expert Opinion on Investigational Drugs
|
March 7, 2008
Ixabepilone for the treatment of solid tumors: a review of clinical data
Neelima Denduluri, Sandra M Swain
Expert Opinion on Pharmacotherapy
|
January 24, 2012
Avastin withdrawal symptoms
Filipa Lynce, Sandra M Swain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2011
Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?
Nitin Verma, Sandra M Swain
Oncology (Williston Park, N.Y.)
|
May 27, 2014
Pertuzumab: increasing the options
Raquel Nunes, Sandra M Swain
Page
of 21
Search research articles
Search
Showing results (11-20 of 210) with videos related to
Sort By:
Page
of 21
Journal of the National Cancer Institute
|
November 25, 2010
Meta-analysis: should it be more than the sum of its parts?
Pia Herbolsheimer, Sandra M Swain
NPJ Breast Cancer
|
May 21, 2021
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Ilana Schlam, Sandra M Swain
Expert Opinion on Drug Safety
|
March 17, 2016
Pertuzumab for the treatment of breast cancer: a safety review
Jennifer Gao, Sandra M Swain
Clinical Breast Cancer
|
December 15, 2010
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer
José Baselga, Sandra M Swain
Cancer
|
May 27, 2010
Primary systemic chemotherapy for inflammatory breast cancer
Sarah Sinclair, Sandra M Swain
Nature Reviews. Cancer
|
June 19, 2009
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
José Baselga, Sandra M Swain
Expert Opinion on Investigational Drugs
|
March 7, 2008
Ixabepilone for the treatment of solid tumors: a review of clinical data
Neelima Denduluri, Sandra M Swain
Expert Opinion on Pharmacotherapy
|
January 24, 2012
Avastin withdrawal symptoms
Filipa Lynce, Sandra M Swain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2011
Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?
Nitin Verma, Sandra M Swain
Oncology (Williston Park, N.Y.)
|
May 27, 2014
Pertuzumab: increasing the options
Raquel Nunes, Sandra M Swain
Page
of 21